Malaria Vaccine: Complete 2026 Guide to RTS,S (Mosquirix) and R21/Matrix-M — Efficacy, Rollout, Safety & the Future

By Dr. Sagar Rajkuwar (MS-ENT), Prabha ENT Clinic, Ambad, Nashik, Maharashtra, India · 🌐 www.entspecialistinnashik.com

Short answer: As of 2026, two WHO-recommended malaria vaccines are in use for children living in malaria-endemic Africa: RTS,S/AS01 (Mosquirix, GlaxoSmithKline, WHO-recommended October 2021) and R21/Matrix-M (University of Oxford + Serum Institute of India, WHO-recommended October 2023). Both target the Plasmodium falciparum circumsporozoite protein (CSP) and reduce clinical malaria by approximately 30–40% (RTS,S) and up to 75% (R21) in the first year after a 3-dose primary series. By 2026 more than 20 African countries have begun routine childhood malaria vaccine rollout through Gavi, with over 25 million doses delivered. The malaria vaccine is an addition to — not a replacement for — bed nets, indoor spraying, chemoprevention and prompt diagnosis and treatment.

📑 Table of Contents

1. Introduction — Why a Malaria Vaccine Matters
2. Historical Timeline of Vaccine Development
3. How the Malaria Vaccine Works
4. RTS,S/AS01 (Mosquirix) — Full Profile
5. R21/Matrix-M — Full Profile
6. Comparison Table — RTS,S vs R21
7. Dosing Schedule & Age Target
8. Efficacy Evidence
9. Safety Profile
10. Who Should Get It — Eligibility
11. Contraindications
12. Rollout — Country-by-Country 2024–2026
13. Role of Gavi, WHO & UNICEF
14. Cost, Supply and Access
15. Malaria Vaccine in Travellers?
16. Future Vaccines — mRNA, PfSPZ, Blood-Stage, Transmission-Blocking
17. Myths vs Facts
18. Frequently Asked Questions
19. Summary
20. Conclusion
21. References

1) Introduction — Why a Malaria Vaccine Matters

After more than a century of research, 2021 marked a landmark year — WHO recommended the first-ever malaria vaccine for widespread use in children. In 2023, a second, more effective malaria vaccine followed. Together they represent one of the most important advances in global health, saving tens of thousands of African children each year. With 597,000 malaria deaths in 2023 (WHO), 76% in children under 5, every additional tool is critical.

2) Historical Timeline of Vaccine Development

• 1965 — First attempt with irradiated sporozoites by Nussenzweig et al.
• 1987 — GSK and Walter Reed Army Institute begin RTS,S development
• 2015 — European Medicines Agency gives positive scientific opinion on RTS,S
• 2019 — Pilot rollout of RTS,S in Ghana, Kenya, and Malawi (MVIP)
• October 2021 — WHO recommends RTS,S for broader use
• 2021 — Phase II data of R21 published showing 77% efficacy
• October 2023 — WHO recommends R21/Matrix-M
• January 2024 — First routine R21 doses given in Ivory Coast and Central African Republic
• 2024–2026 — Gavi-supported rollout expands to 20+ African countries

3) How the Malaria Vaccine Works

Both licensed vaccines target the circumsporozoite protein (CSP) on the sporozoite stage of P. falciparum. The CSP is the dominant surface protein of sporozoites injected by mosquitoes; antibodies against it neutralise the parasite before it can invade liver cells.

RTS,S Platform

Virus-like particle fusing a portion of CSP with hepatitis B surface antigen (HBsAg), expressed in yeast and formulated with the AS01 adjuvant system (MPL + QS-21 + liposome).

R21 Platform

Similar CSP-HBsAg virus-like particle but with a higher CSP-to-HBsAg ratio and a smaller, saponin-based Matrix-M adjuvant, giving stronger immunogenicity at lower antigen dose and lower cost.

4) RTS,S/AS01 (Mosquirix) — Full Profile

• Developer: GSK + PATH Malaria Vaccine Initiative
• Approval: EMA positive opinion 2015; WHO recommendation October 2021
• Schedule: 4 doses — 5, 6, 7 months + booster at 15–18 months
• Pilot countries: Ghana, Kenya, Malawi (Malaria Vaccine Implementation Programme — MVIP)
• Efficacy: ~ 30% reduction in clinical malaria over 4 years; ~ 50% reduction in severe malaria during first year; 13% reduction in all-cause mortality in pilot countries
• Supply: 18 million doses allocated to 12 countries by Gavi 2023–2025
• Cost: ~ US$ 9.3 per dose at launch

5) R21/Matrix-M — Full Profile

• Developer: Jenner Institute, University of Oxford + Serum Institute of India
• Approval: WHO recommendation October 2023; prequalified December 2023
• Schedule: 4 doses — 5, 6, 7 months + booster at ~ 18 months (one month before high-transmission season in seasonal settings)
• Efficacy: Phase III (Burkina Faso, Mali, Kenya, Tanzania, 4800 children): 75% reduction over 12 months in seasonal settings; 68% in standard settings
• Supply: Serum Institute of India can manufacture up to 100 million doses per year
• Cost: Target US$ 2–4 per dose
• Status: Routine use in Ivory Coast, South Sudan, Central African Republic, Burkina Faso, Nigeria, DRC, and others by 2026

6) Comparison Table — RTS,S vs R21

7) Dosing Schedule & Age Target

Both malaria vaccine products are given to infants in endemic Africa from 5 months of age. The 3-dose primary series is given 1 month apart at 5, 6, and 7 months, followed by a 4th booster around 18 months. In seasonal transmission settings, 3 pre-season annual doses can be used (R21). The vaccine is given intramuscularly in the anterolateral thigh (infants) or deltoid (older children).

8) Efficacy Evidence

RTS,S Pivotal Trials

• Phase III RTS,S-MAL-055 trial (2009–2014, 15,460 children) — ~ 36% efficacy over 4 years in children 5–17 months at first dose
• MVIP real-world data (2019–2023, 1.7 million children) — 13% reduction in all-cause mortality and 22% reduction in severe malaria hospitalisation

R21 Pivotal Trials

• Phase II (Burkina Faso, 450 children) — 77% efficacy over 12 months in seasonal setting; sustained with booster
• Phase III (4800 children in 5 African sites) — 75% seasonal efficacy, 68% standard-site efficacy, favourable safety

Modelled Impact

WHO modelling projects both malaria vaccines could prevent 400,000+ deaths and 60 million clinical cases annually when fully scaled.

9) Safety Profile

• Most common side effects: fever, injection-site soreness, irritability, mild rash
• Febrile seizures observed slightly more often in week after dose 3 or 4 — generally brief and benign
• No increase in meningitis signal confirmed in extended MVIP follow-up (initial Phase III imbalance resolved)
• No autoimmune, neurological, or long-term safety concerns
• No evidence of altered immune response to other childhood vaccines when co-administered
• R21 safety profile mirrors RTS,S with slightly lower reactogenicity

10) Who Should Get It — Eligibility

• Infants ≥ 5 months living in moderate-to-high P. falciparum transmission areas (WHO)
• Priority to areas with annual parasite prevalence ≥ 10%
• Catch-up vaccination for children up to 5 years in some countries
• Co-delivered with routine EPI vaccines where feasible

11) Contraindications

• Severe allergic reaction to a prior malaria vaccine dose or any component
• Acute severe febrile illness — delay dose until recovery
• Known hypersensitivity to vaccine excipients
• Immunocompromised children should still be vaccinated — benefit outweighs risk

12) Rollout — Country-by-Country 2024–2026

• Ghana, Kenya, Malawi — pilot MVIP countries, now routine
• Cameroon — first non-pilot country to roll out RTS,S (January 2024)
• Ivory Coast — first country to roll out R21 (July 2024)
• Central African Republic, South Sudan, Burkina Faso, DRC, Nigeria, Benin, Burundi, Liberia, Niger, Sierra Leone, Uganda — joined 2024–2026
• By end-2026, > 20 African countries have introduced a malaria vaccine into routine immunisation

13) Role of Gavi, WHO & UNICEF

Gavi, the Vaccine Alliance finances procurement; UNICEF handles cold-chain supply; WHO issues policy guidance and surveillance frameworks; PATH and the Jenner Institute support implementation research. The African Vaccine Manufacturing Accelerator funds continental vaccine production. The malaria vaccine is now a core component of Gavi 6.0 strategy (2026–2030).

14) Cost, Supply and Access

R21/Matrix-M at US$ 2–4 per dose makes it the most affordable malaria vaccine ever produced. Serum Institute of India’s capacity of 100 million doses per year is projected to meet global demand. By 2030, Gavi aims to vaccinate 100 million African children through combined RTS,S and R21 programmes.

15) Malaria Vaccine in Travellers?

Current licensed vaccines are approved only for children in endemic areas, not for adult travellers. Travellers continue to rely on chemoprophylaxis (atovaquone-proguanil, doxycycline, mefloquine, tafenoquine) and personal protection measures. A separate traveller-focused vaccine (PfSPZ, Sanaria) is in Phase III.

16) Future Vaccines — mRNA, PfSPZ, Blood-Stage, Transmission-Blocking

• PfSPZ (Sanaria) — attenuated whole sporozoite, Phase III, promising in adults
• mRNA malaria vaccines — BioNTech BNT165 and NIH candidates in Phase I/II
• Blood-stage vaccines targeting PfRH5 — early trials showing broad efficacy
• Transmission-blocking vaccines targeting Pfs25 and Pfs230 — community-level impact
• P. vivax vaccines targeting Duffy-binding protein (PvDBP) — currently in Phase I
• Combination multistage vaccines — future direction

17) Myths vs Facts

• ❌ The malaria vaccine gives 100% protection. ✅ 30–75% efficacy depending on vaccine and setting; still life-saving at scale.
• ❌ Vaccinated children do not need bed nets. ✅ Combined ITNs + vaccine reduce incidence much more than either alone.
• ❌ Vaccination causes autism or infertility. ✅ No evidence; myths rejected by WHO and all regulatory agencies.
• ❌ Travellers can take the malaria vaccine instead of pills. ✅ Not yet — chemoprophylaxis remains standard.
• ❌ Only African children can benefit. ✅ Future P. vivax and traveller vaccines will extend reach.

18) Frequently Asked Questions

Q1. Does the malaria vaccine replace bed nets and drugs?

No. WHO insists on an integrated approach — ITNs, indoor spraying, chemoprevention, prompt diagnosis and treatment, and vaccination.

Q2. Why only children?

Children under 5 bear 76% of malaria deaths. Vaccinating this age group has the highest public-health payoff.

Q3. How long does the malaria vaccine protect?

Protection wanes after 12–18 months; a 4th booster dose restores efficacy. Longer-duration formulations are in development.

Q4. Is the malaria vaccine safe with other childhood vaccines?

Yes — co-administration with EPI vaccines (DTP, measles, pneumococcal, rotavirus) is safe and effective.

Q5. Can adults receive the malaria vaccine?

Not routinely — current indication is for children in endemic Africa. Adult traveller vaccines are in late-phase trials.

Q6. Is R21 better than RTS,S?

R21 shows higher efficacy at lower cost and larger supply but shorter follow-up. WHO recommends both; country choice depends on supply.

Q7. Why does the malaria vaccine need 4 doses?

Antibody levels after 3 doses fall rapidly. The 4th booster at 18 months markedly extends protection.

Q8. Will the malaria vaccine eliminate malaria?

Not alone. Combined with vector control, chemoprevention, and future transmission-blocking vaccines, it is a key piece of the elimination strategy.

Q9. Can pregnant women receive the malaria vaccine?

Current licensure is for infants; pregnancy use is being studied.

Q10. Is India using the malaria vaccine?

India has not yet rolled out the malaria vaccine in its national programme because dominant species is P. vivax; vivax-targeted vaccines are in development. India (via Serum Institute) is the world’s largest producer of R21.

19) External Video Resource

▶️ WHO: Malaria vaccines explained — RTS,S and R21 (YouTube)

20) Summary

The world now has two WHO-recommended malaria vaccines: RTS,S/AS01 (Mosquirix) since 2021 and R21/Matrix-M since 2023. Both target the CSP of P. falciparum, are given in 4 doses from 5 months of age, and are rolling out across 20+ African countries. R21 offers higher efficacy at lower cost with vastly greater supply. Expected combined impact: hundreds of thousands of child deaths averted annually. Vaccination complements — never replaces — bed nets, chemoprevention, and prompt treatment.

21) Conclusion

The arrival of effective malaria vaccines is the biggest advance in malaria control in a generation. Alongside artemisinin-based combination therapies, insecticide-treated nets, and new vector-control tools, it brings the goal of malaria elimination significantly closer. Continued investment in next-generation vaccines (PfSPZ, mRNA, blood-stage, transmission-blocking, P. vivax) is essential to finish the job.

22) Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. The malaria vaccine is given through national immunisation programmes. Decisions on vaccination for your child or community must be made in consultation with qualified public-health authorities and healthcare providers. Call 108 (India) or 911 (USA) for emergencies.

23) References

1. World Health Organization. WHO recommends RTS,S/AS01 malaria vaccine for broader use. October 2021.
2. World Health Organization. WHO recommends R21/Matrix-M malaria vaccine. October 2023.
3. Datoo MS et al. R21/Matrix-M malaria vaccine Phase III trial. Lancet 2024.
4. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01. Lancet 2015; 386:31–45.
5. WHO Malaria Vaccine Implementation Programme (MVIP) Report, 2023.
6. Gavi, the Vaccine Alliance — Malaria Vaccine Programme Portfolio, 2024–2026.
7. Serum Institute of India — R21 production update 2024.
8. WHO World Malaria Report 2024.
9. Draper SJ et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe 2024.
10. UNICEF Malaria Vaccine Market Update, 2024.

Related reading: Malaria Symptoms — 2026 Doctor’s Guide · Malaria Treatment — WHO 2026 Guide · Is There a Cancer Vaccine Available in the USA?